Gefitinib 184475-35-2
Gefitinib (INN) (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets proteins in malignant cells. It is marketed by AstraZeneca and Teva under the trade name Iressa.
| Systematic (IUPAC) name: |
N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine |
| Gefitinib CAS number: |
184475-35-2 |
| ATC code: |
L01XE02 |
| PubChem: |
123631 |
| DrugBank: |
APRD00997 |
| Formula: |
C22H24ClFN4O3 |
| Molecular mass: |
446.902 g/mol |
| Gefitinib Assay/Purity: |
Typically NLT 98% |
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
